LXRX Valuation

Lexicon Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.210

+0.01(0.833%)1D

Overview
Forecast
Valuation
Earnings

LXRX Relative Valuation

LXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LXRX is overvalued; if below, it's undervalued.

Historical Valuation

Lexicon Pharmaceuticals Inc (LXRX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 28.53 is considered Overvalued compared with the five-year average of -4.41. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 0.66 to 1.00 according to relative valuation methord. Compared to the current price of 1.25 USD , Lexicon Pharmaceuticals Inc is Overvalued By 24.16%.

Relative Value

Fair Zone

0.66-1.00

Current Price：1.25

24.16%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.54

P/B

Median3y

3.08

Median5y

2.76

-37.71

FCF Yield

Median3y

-39.70

Median5y

-31.94

Competitors Valuation Multiple

The average P/S ratio for LXRX's competitors is 8.56, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX) exhibits a P/S ratio of 28.53, which is 233.11% above the industry average. Given its robust revenue growth of 11.68%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LXRX.O

Lexicon Pharmaceuticals Inc

28.53

Average P/S: 8.56

11.68%